PARP1 and ovarian carcinoma: Overall, these results suggest that the addition of ATO sensitizes HR-proficient ovarian cancer cells to the PARP inhibitors, especially olaparib and fluazolepali, though the optimized efficacy appears at specific concentrations for each drug.